Abstract: Certain aspects of the present disclosure include compounds having Formula (X). Disclosed embodiments also include compositions comprising at least one compound according to the present disclosure, such as from 5% to 70% of at least one compound according to the present disclosure, at a dosage of from 0.1 mg to about 10,000 mg, and further comprising an excipient, an adjuvant, a carrier, and/or at least one additional biologically active compound other than a compound according to the present disclosure. Disclosed compounds and/or can be administered to a subject multiple times per day, such as 1 to 3 times per day, and/or periodically, such as every 2 to 7 days, for a variety of reasons, such as to increase neuronal plasticity, to treat a neurological disease, to treat a neuropsychiatric disease, to elicit a biological response, such as by activating a 5-HT2A receptor, or to increase at least one of translation, transcription, or secretion of neurotrophic factors.

Abstract: The present disclosure relates to compounds Formula (I): methods for making the compounds and methods for their use.

Abstract: Disclosed herein are 2-bromo-LSD analogs of Formula (I) or a pharmaceutically acceptable salt thereof, as well as methods for making and using the compounds to, for example, treat neuropsychiatric disorders.

Abstract: Disclosed herein are xanomeline analogs, as well as methods for making and using the analogs to, for example, treat neuropsychiatric disorders.

Abstract: Disclosed herein are isotopically enriched compounds of 2-bromolysergic acid diethylamide, LSD, ALD-52, and 1P-LSD, as well as methods for their use in treating neurologic and brain disorders.

Abstract: Compounds for activating invariant natural killer T cells (iNKT) cells are provided. Compounds according to certain embodiments activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFN?, IL-2, IL-4, IL-6 and TNF?. In some embodiments, activated iNKT cells are used to selectively reduce the presence of or eliminate inflammatory senescent cells, such as senescent cells having an inflammatory secretome (SASP). Methods for activating iNKT cells by contacting an iNKT cell with an amount of the subject compounds and selectively reducing the presence of or eliminating senescent cells with activated iNKT cells are also described. Compositions for practicing the subject methods are also described.

Abstract: Disclosed herein are salt and solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine. The solid form may be a salt and/or a crystalline form of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, such as a polymorph of N-eth-yl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The solid forms of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Disclosed herein are salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate (4-OH-DIPT), e.g., 4-OH-DIPT hemi-glutarate, 4-OH-DIPT hemi-succinate, 4-OH-DIPT hemi-succinate hydrochloride, and 4-OH-DIPT hemi-glutarate hydrochloride. The solid form may be a salt and/or a crystalline form of the 4-OH-DIPT, such as a polymorph of 4-OH-DIPT or a salt thereof. Also disclosed are methods for making the solid forms and methods for administering the solid forms. The disclosed solid forms of 4-OH-DIPT are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Described herein are isotopically enriched analogs of methylone (e.g., deuterated analogs of methylone (e.g., (S)-methylone and (R)-methylone) with improved characteristics. Also described herein are salts (such as hydrochloride salt) and solid forms (e.g., crystalline forms) of methylone. Also described herein are stereoisomers (e.g., enantiomers) of methylone. The present disclosure also provides methods of making and methods of use of the methylone or methylone analogs and solid forms of 3,4-methylenedioxy-N-ethylcathinone hydrochloride described herein to treat brain and neurological disorders such as depression.

Abstract: The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to Formula (I): wherein X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.

Abstract: Disclosed herein are isotopically enriched compounds and methods of using both isotopically and non-isotopically enriched compounds of the following formula in the treatment of neurologic and brain disorders/conditions.

Abstract: Disclosed herein are salts and solid state forms of psilocybin, including psilocybin HCl, and salts and solid forms of O-acetylpsilocin, including O-acetylpsilocin fumarate. Also disclosed are methods for making the salts and solid forms and methods for administering the salts and solid forms. The salts and solid forms disclosed herein are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

Abstract: Deuterium-containing analogs/derivatives of N,N,N-trimethyl-4-phosphoryloxytryptamine are disclosed. The deuterated compounds can be incorporated into pharmaceutical compositions and used to treat diseases such as psychological diseases and disorders.

Abstract: Disclosed herein are xanomeline analogs, as well as methods for making and using the analogs to, for example, treat neuropsychiatric disorders.

Abstract: Described herein are isotopically enriched analogs of methylone (e.g., deuterated analogs of methylone (e.g., (S)-methylone and (R)-methylone) with improved characteristics. Also described herein are salts (such as hydrochloride salt) and solid forms (e.g., crystalline forms) of methylone. Also described herein are stereoisomers (e.g., enantiomers) of methylone. The present disclosure also provides methods of making and methods of use of the methylone or methylone analogs and solid forms of 3,4-methylenedioxy-N-ethylcathinone hydrochloride described herein to treat brain and neurological disorders such as depression.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to Formula (I): wherein X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.

Abstract: Compounds as depicted below and structural analogues thereof for activating invariant natural killer T cells (iNKT) cells are provided. Such compounds may be used to activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFN?, IL-2, IL-4, IL-6 and TNF?. Activated iNKT cells may be used to selectively reduce the presence of or eliminate inflammatory senescent cells, such as senescent cells having an inflammatory secretome (SASP). Also provided are pharmaceutical compositions comprising such compounds.

Abstract: Disclosed herein are apyrase inhibitors of Formula (I) Also disclosed herein are methods for using the disclosed inhibitors, including in methods for protecting crops from pests. In one aspect the apyrase inhibitors are useful for enhancing the activity of pesticides for the protection of crops from pathogens and to support crop yield.